- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00932243
Bacteremia in Intensive Care Unit (ICU)
Bacteremia in Intensive Care Unit (ICU) and the Role of Toll-Like-Receptors (TLRs)
Study Overview
Status
Conditions
Detailed Description
INTRODUCTION Bacteremia is associated with significant morbidity and mortality in critically ill patients and increased the length of hospitalization. Incidence of bacteremia in Intensive Care Units ranges from 8 to 10% and mortality 40%.
Risk factors for the development of bacteremia include the presence of central intravascular catheters, hemodialysis, the use of parenteral nutrition, urine catheters, endotracheal tubes, mechanical ventilation, underlying diseases like cancer, various immunocompromised states, mellitus diabetes, malnutrition, renal and liver failure, transplantations, surgery operations, burns.
The most common microbial pathogens which cause bacteremia are Gram negative pathogens, Pseudomonas species, Staphylococcus aureus, Klebsiella species, Pseudomonas aeruginosa, Candida albicans, Acinetobacter baumanii, Streptococcus pneumoniae.
Toll-like receptors (TLRs) are important for the activation of innate immunity against microbial pathogens. TLRs are transmembrane proteins and are composed of leukine rich extracellular domain, a short intramembrane segment and an intracytoplasmic domain. Intracytoplasmic domain is similar to that of interleukin-1 (IL-1) receptor.
In humans, they have been identified eleven types of recognizing specific pathogen-associated molecular patterns (PAMPs). TLR1 and TLR2 form a heterodimer recognizing bacterial tri-acylated lipopeptides of Gram-positive bacteria. TLR2 and TLR6 form another heterodimer recognizing di-acylated lipopeptides of Gram-positive bacteria. TLR4 is a heterodimer recognizing lipopolysacharedes (LPS)of Gram-negative bacteria while TLR5 is a receptor recognizing flagellae of Gram-negative bacteria. All these aforementioned types of TLRs are expressed on the outer surface of the cell membrane. TLR3, TLR7 TRL8 and TLR9 is a group of receptors expressed on an internal surface of the phagosomes formed in the cytoplasm after the ingestion of the pathogens.TLR3 recognizes viral dsRNA, TLR7 recognizes imidazol-quinollines, TLR8 recognize ssRNA and TLR9 recognize non-methylated bacterial CpG DNA. In addition to bacterial and viral CpG DNA, TLR9 is presumably involved in pathogenesis of autoimmune disorders. TLR10 and TLR11 are still under investigation, although TLR11 seem to recognize uropathogenic bacteria.
We suppose that the presence of bacteremia and sepsis in percent of critically ill patients and none at all, associated with different expression and faction of TLRs Searching of genetic polymorphisms of TLRs which associated with the presence of bacteremia and sepsis in ICU patients, probably will help us to clarify the pathophysiology of sepsis.
Aim
The study is a perspective cohort study which aimed to:
- Search of genetic polymorphisms of TLRs which associated with the presence of bacteremia and sepsis in ICU patients
- Estimate the incidence of bacteraemia
- Search the microbiology of bacteremia
Correlate the incidence of bacteraemia with clinical parameter, significant for the nursing of critically ill patients in ICU like:
Α) the duration of nursing Β) the outcome of nursing
- Correlate the incidence of bacteraemia with probable risk factors like:
A) Bronchoscope B) Hemodialysis C) Mechanical ventilation D) Use of central intravascular catheters E) Tracheostomy F) Use of parenteral nutrition G) Use of central intravascular catheters with antiseptic substance
MATERIALS AND METHOD
Settings: The study will be performed in ICU, University Hospital of Larissa (10 beds).
Participants: Participants in the study will be all the patients who will be nursed in ICU for a two years period and they will be studied for all stay in ICU until their transfer to other ward or until their death. Criterion of exclusion of patients from the study will constitute the time of hospitalisation of patients that will be smaller than 24 hours.
Tools: The estimate of incidence of bacteremia but also the investigation of her microbiological explanation and the estimate of her repercussions for the patients it is used the Protocol of Bacteremia This protocol consist data as general elements, elements that concern the bacteremia as the samples, the micro-organisms, the resistance in the antibiotics, the mechanic ventilation, risk factors for growth of bacteremia, the empiric issuing of antibiotics but also the elements of outcomes of patients.
Diagnosis of bacteremia will be based on Centre of Disease Control end Prevention (CDC) criteria.
For the laboratorial detection of polymorphisms of TLR9 will be taken blood samples from the patients in the three first days of their nursing and will be sent in laboratory for analysis. For the laboratorial confirmation of bacteremia will be taken blood cultures or percutaneous or via intravenous catheters, which will be sent for analysis in the laboratory. Each result of blood culture will be also accompanied by the antibiogram according to which will be determined also the therapeutic form of antibiotics from the servant doctors. The reception of blood cultures will be realised in each change of central catheters and in the appearance of fever wave.
The follow-up of patients will become in daily base and essential information will be collected through the cards of nursing and the files of patients with the laboratorial results.
For the estimate of gravity of patients will be used APACHE II Score, Glasgow Scale, and SOFA Scale.
Statistic Analysis:
The statistic analysis of data will be realised with the use of computational parcel of SISS 15.0 for Windows. Data will be compared between bacteremia and no bacteremia groups. The investigation of relation of various potential risk factors with the repercussion of bacteremia, will be realised with the bivariate and multivariate analysis and the statistical method of simple accountant regression (simple Logistic Regression) and multiple accountant regression (multiple Logistic Regression). The odds ratio (OR) and linear coefficient will be calculated and presented with 95% CI. P<0.05 will be considered statistically significant.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Mezourlo
-
Larisa, Mezourlo, Greece, 41335
- Zakynthinos E
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- presence in Intensive Care Unit
Exclusion Criteria:
- Length of stay <24 hours
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria Chatzi, RN,MSc,ICU, University Hospital Larisa
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 845UT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacteremia and Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Aimee LiCompleted
-
University Hospital, GrenobleCEA - LetiNot yet recruiting
-
Vanderbilt University Medical CenterCompletedBloodstream Infection | Vancomycin | MRSA Bacteremia | Sepsis BacterialUnited States
-
Istanbul Medipol University HospitalRecruitingFungemia | Bloodstream Infections | Bacteremia and SepsisTurkey (Türkiye)
-
University Hospital, GrenobleGenMark DiagnosticsCompletedFungemia | Bacteremia SepsisFrance
-
PATH EX, Inc.Active, not recruitingSepsis | Infection | Systemic Inflammatory Response Syndrome (SIRS) | Bacteremia SepsisArmenia
-
Seoul National University HospitalCompletedHematologic Diseases | Bacteremia SepsisKorea, Republic of
-
Resistell AGInnosuisse - Swiss Innovation AgencyCompleted
-
Instituto de Investigacion Sanitaria La FeWithdrawnSepsis Affecting Skin | Central Venous Catheter Related Bacteremia